keyword
MENU ▼
Read by QxMD icon Read
search

long term effects of proton pump inhibitors

keyword
https://www.readbyqxmd.com/read/28780717/proton-pump-inhibitors-in-gastroesophageal-reflux-disease-friend-or-foe
#1
REVIEW
C Prakash Gyawali
PURPOSE OF REVIEW: Proton pump inhibitor (PPI) use in gastroesophageal reflux disease (GERD) has been redefined, in light of recent advances highlighting GERD phenotypes that respond to PPIs, and fresh revelations of potential risks of long-term PPI therapy. RECENT FINDINGS: Erosive esophagitis predicts excellent response to PPI therapy, but non-erosive reflux disease (NERD) with abnormal reflux parameters on ambulatory reflux monitoring also demonstrates a similar response...
September 2017: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/28763306/efficacy-and-safety-of-proton-pump-inhibitors-in-the-long-term-aspirin-users-a-meta-analysis-of-randomized-controlled-trials
#2
Khagendra Dahal, Sharan P Sharma, Jaspreet Kaur, Billie J Anderson, Gurpinder Singh
BACKGROUND: Long-term aspirin use in cardiovascular disease prevention may result in gastrointestinal bleeding. Although proton pump inhibitors (PPI) have been shown to reduce the risks of peptic ulcers and dyspeptic symptoms in long-term aspirin users in the randomized controlled trials, there are safety concerns about the long-term use of PPI. STUDY QUESTION: What is the safety and efficacy of PPI in patients using aspirin in long term for prevention of cardiovascular diseases and stroke? METHODS: We searched MEDLINE, EMBASE, CENTRAL, CINAHL, ProQuest, and relevant references from inception through February 2015, and used random-effects model for meta-analysis...
July 26, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28761572/a-case-of-severe-iron-deficiency-anemia-associated-with-long-term-proton-pump-inhibitor-use
#3
REVIEW
David N Dado, Erin B Loesch, Sudha P Jaganathan
The use of proton pump inhibitors (PPIs) in the treatment of gastrointestinal diseases has evolved over recent years. Initially intended for short-term use, PPIs are increasingly being used, often inappropriately, as long-term maintenance medications. The mechanism of action of PPIs is suppression of gastric basal and stimulated acid secretion by inhibiting the parietal cell H(+)/K(+) ATP pump with a resultant increase in gastric pH and hypo- or achlorhydria. Although short-term use is related to few adverse effects, long-term use is associated with numerous complications...
2017: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/28754388/rationale-design-and-baseline-characteristics-of-participants-in-the-cardiovascular-outcomes-for-people-using-anticoagulation-strategies-compass-trial
#4
Jackie Bosch, John W Eikelboom, Stuart J Connolly, Nancy Cook Bruns, Vivian Lanius, Fei Yuan, Frank Misselwitz, Edmond Chen, Rafael Diaz, Marco Alings, Eva M Lonn, Petr Widimsky, Masatsugu Hori, Alvaro Avezum, Leopoldo S Piegas, Deepak L Bhatt, Kelley R H Branch, Jeffrey L Probstfield, Yan Liang, Lisheng Liu, Jun Zhu, Aldo P Maggioni, Patricio Lopez-Jaramillo, Martin O'Donnell, Keith A A Fox, Ajay Kakkar, Alexander N Parkhomenko, Georg Ertl, Stefan Störk, Katalin Keltai, Matyas Keltai, Lars Ryden, Gilles R Dagenais, Nana Pogosova, Antonio L Dans, Fernando Lanas, Patrick J Commerford, Christian Torp-Pedersen, Tomasz J Guzik, Peter B Verhamme, Dragos Vinereanu, Jae-Hyung Kim, Jong-Won Ha, Andrew M Tonkin, John D Varigos, Basil S Lewis, Camilo Felix, Khalid Yusoff, Philippe Gabriel Steg, Victor Aboyans, Kaj P Metsarinne, Sonia S Anand, Robert G Hart, Andre Lamy, Paul Moayyedi, Darryl P Leong, Mukul Sharma, Salim Yusuf
BACKGROUND: Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy. METHODS: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) is a double-blind superiority trial comparing rivaroxaban 2...
August 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28721975/effect-of-long-term-proton-pump-inhibitor-administration-on-gastric-mucosal-atrophy-a-meta-analysis
#5
REVIEW
Zhong Li, Cong Wu, Ling Li, Zhaoming Wang, Haibin Xie, Xiaozhou He, Jin Feng
BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related gastrointestinal diseases. Recently, some studies have reported that PPIs can alter the gastric mucosal architecture; however, the relationship remains controversial. This meta-analysis study was designed to quantify the association between long-term PPI administration and gastric atrophy. MATERIALS AND METHODS: A PubMed search was conducted to identify studies using the keywords proton pump inhibitors or PPI and gastric atrophy or atrophic gastritis; the timeframe of publication searched was up to May 2016...
July 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28707172/long-term-outcomes-of-laparoscopic-sleeve-gastrectomy-a-single-center-retrospective-study
#6
Piotr K Kowalewski, Robert Olszewski, Maciej S Walędziak, Michał R Janik, Andrzej Kwiatkowski, Natalia Gałązka-Świderek, Krzysztof Cichoń, Jakub Brągoszewski, Krzysztof Paśnik
INTRODUCTION: Sleeve gastrectomy (LSG) is one of the most popular bariatric procedures. We present our long-term results regarding weight loss, comorbidities, and gastric reflux disease. MATERIAL AND METHODS: We identified patients who underwent LSG in our institution between 2006 and 2009. We revised the data, and the patients with outdated contact details were tracked with the national health insurance database and social media (facebook). Each of the identified patients was asked to complete an online or telephone survey covering, among others, their weight and comorbidities...
July 13, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28680175/outcome-after-discontinuation-of-proton-pump-inhibitors-at-a-residential-care-site-quality-improvement-project
#7
Candy Lee, Anita Lo, Kiran Ubhi, Michael Milewski
BACKGROUND: Increased prescribing of proton pump inhibitors (PPIs) in the past few decades can be attributed mainly to long-term use of this type of therapy. Recent evidence indicates signals of harm associated with long-term use of PPIs, such as increased risk of Clostridium difficile infection, recurrence of C. difficile infection, and fracture. A few studies have assessed the effectiveness of step-down management of patients receiving long-term PPI therapy in ambulatory care settings...
May 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28657473/vonoprazan-fumarate-for-the-management-of-acid-related-diseases
#8
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino
Proton pump inhibitors (PPIs) display a number of limitations and unmet clinical needs that have prompted the development of novel drugs to improve the outcomes of acid-related diseases, including the eradication of H. pylori. In this context, a new synthesized potassium-competitive acid blocker (P-CAB), vonoprazan, showed higher suppression of gastric acid secretion. Areas covered: This review discusses the current knowledge regarding the efficacy of vonoprazan in the treatment of acid-related diseases, with a particular focus on its use in Helicobacter pylori eradication...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28651024/short-term-proton-pump-inhibitor-treatment-may-cause-hypomagnesaemia-in-critically-ill-patients-a-pilot-study
#9
Łukasz J Krzych, Piotr Łój, Teresa Nowak, Wojciech Kazura, Piotr Knapik
Many studies have suggested a link between long-term PPI treatment and hypomagnesaemia, though none of them investigated the short-term exposure in high-risk patients. We sought to investigate this issue in 90 critically ill patients. We assessed serum Mg concentrations, necessity of Mg supplementation, PPI dose, duration of PPI therapy and route of administration. In multiple analysis we found that Mg supplementation (positive effect/p=0.03) and enteral route of PPI administration (negative effect/p=0.02) had significant impact on Mg concentration...
June 24, 2017: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/28618191/a-proton-pump-inhibitor-in-the-reformulation-setting-bioequivalence-and-potential-implications-for-long-term-safety
#10
E Dubcenco, P M Beers-Block, L P Kim, P Schotland, J G Levine, C A McCloskey, E D Bashaw
Proton pump inhibitors (PPIs) have become known for both their therapeutic effect and good safety profile. An application was submitted to the US Food and Drug Administration for approval of a reformulated PPI product that failed bioequivalence testing, but was submitted on the basis of the long history of PPI use as a "surrogate" for equivalence. This review evaluates the safety data for PPIs, discuss variability of pharmacokinetic parameters of PPIs in the reformulation setting, and potential implications of those changes for long-term safety...
June 15, 2017: Clinical and Translational Science
https://www.readbyqxmd.com/read/28578848/study-on-pharmacokinetics-and-bioequivalence-of-vonoprazan-pyroglutamate-in-rats-by-liquid-chromatography-with-tandem-mass-spectrometry
#11
Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu, Qingwei Wang
Vonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs). However, the clinical applications of TAK0-438F suffers limitation due to the lack of injection dosage form. Efforts to overcome this limitation lead to the systhesis of Vonoprazan pyroglutamate (TAK-438P) for its high water solubility and more potent antisecretory effect. This was the first report to establish and validate a reliable and sensitive LC-MS/MS method for the quantification of TAK-438P in rat plasma and tissues (heart, liver, spleen, liver, kidney, rain, stomach and small intestine)...
August 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28565788/immunosuppressive-agents-are-associated-with-peptic-ulcer-bleeding
#12
Minoru Tomizawa, Fuminobu Shinozaki, Rumiko Hasegawa, Yoshinori Shirai, Yasufumi Motoyoshi, Takao Sugiyama, Shigenori Yamamoto, Naoki Ishige
Peptic ulcer bleeding can be fatal. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and immunosuppressive agents are administered for long-term usage. The present study assessed the association between peptic ulcer bleeding and administration of NSAIDs, corticosteroids and immunosuppressive agents. Furthermore, the efficacy of lowering the risk of peptic ulcer bleeding with proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) was evaluated. Medical records were retrospectively analyzed for patients subjected to an upper gastrointestinal (GI) endoscopy performed at the National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan) from October 2014 to September 2015...
May 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28537351/endoluminal-sphincter-augmentation-with-the-muse%C3%A2-system-and-gerdx%C3%A2-system-in-the-treatment-of-gastroesophageal-reflux-disease-a-new-impact
#13
Suyu He, Hubertus Feussner, Simon Nennstiel, Monther Bajbouj, Norbert Hüser, Dirk Wilhelm
To bridge the gap between the long-term intake of proton pump inhibitors (PPIs) and the potential risks of laparoscopic fundoplication, a number of endoscopic procedures for the treatment of gastro-esophageal reflux disease (GERD) have been developed over the past 30 years. Because of the minimally invasive approach, short operative time, and efficacy in selected patients, endoluminal sphincter augmentation appears to be highly attractive. However, most early devices have proven to be unsafe or failed to provide long-term symptom relief...
May 24, 2017: Surgical Technology International
https://www.readbyqxmd.com/read/28487347/acute-and-long-term-effects-of-full-power-electroporation-ablation-directly-on-the-porcine-esophagus
#14
Kars Neven, René van Es, Vincent van Driel, Harry van Wessel, Herma Fidder, Aryan Vink, Pieter Doevendans, Fred Wittkampf
BACKGROUND: Esophageal ulceration and fistula are complications of pulmonary vein isolation using thermal energy sources. Irreversible electroporation is a novel, nonthermal ablation modality for pulmonary vein isolation. A single 200 J application can create deep myocardial lesions. Acute and chronic effects of this new energy source on the esophagus are unknown. METHODS AND RESULTS: In 8 pigs (±70 kg), the suprasternal esophagus was surgically exposed. A linear suction device with a single 35-mm long and 6-mm wide protruding linear electrode inside a plastic suction cup was used for ablation...
May 2017: Circulation. Arrhythmia and Electrophysiology
https://www.readbyqxmd.com/read/28463532/aspirin-and-omeprazole-for-secondary-prevention-of-cardiovascular-disease-in-patients-at-risk-for-aspirin-associated-gastric-ulcers
#15
REVIEW
Guillermo García-Rayado, Carlos Sostres, Angel Lanas
Cardiovascular disease is the most important cause of morbidity and mortality in the world and low-dose aspirin is considered the cornerstone of the cardiovascular disease prevention. However, low-dose aspirin use is associated with gastrointestinal adverse effects in the whole gastrointestinal tract. In this setting, co-therapy with a proton pump inhibitor is the most accepted strategy to reduce aspirin related upper gastrointestinal damage. In addition, some adverse effects have been described with proton pump inhibitors long term use...
August 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28429247/a-review-of-the-novel-application-and-potential-adverse-effects-of-proton-pump-inhibitors
#16
REVIEW
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang
Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H(+)/K(+)-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care. Except for gastric acid-related diseases, PPIs can also be used in the treatment of Helicobacter pylori infection, viral infections, respiratory system diseases, cancer and so on...
May 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28428706/gastroesophageal-reflux-disease-and-morbid-obesity-to-sleeve-or-not-to-sleeve
#17
EDITORIAL
Fabrizio Rebecchi, Marco E Allaix, Marco G Patti, Francisco Schlottmann, Mario Morino
Laparoscopic sleeve gastrectomy (LSG) has reached wide popularity during the last 15 years, due to the limited morbidity and mortality rates, and the very good weight loss results and effects on comorbid conditions. However, there are concerns regarding the effects of LSG on gastroesophageal reflux disease (GERD). The interpretation of the current evidence is challenged by the fact that the LSG technique is not standardized, and most studies investigate the presence of GERD by assessing symptoms and the use of acid reducing medications only...
April 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28424965/assessment-of-drug-drug-interaction-potential-between-ceritinib-and-proton-pump-inhibitors-in-healthy-subjects-and-in-patients-with-alk-positive-non-small-cell-lung-cancer
#18
Yvonne Y Lau, Wen Gu, Tiffany Lin, Kalyanee Viraswami-Appanna, Can Cai, Jeffrey W Scott, Michael Shi
PURPOSE: The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated. METHODS: A healthy subject drug-drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg dose of ceritinib. To further investigate the impact of PPIs on the PK and efficacy of ceritinib in ALK-positive cancer patients, two subgroup analyses were performed. Analysis 1 evaluated ceritinib steady-state trough concentration (Ctrough,ss) and overall response rate (ORR) by concomitant use of PPIs in patients from the ASCEND-1, -2, and -3 studies; analysis 2 evaluated ceritinib single-dose and steady-state AUC0-24h and C max by concomitant PPI use in patients from ASCEND-1 using a definition of PPI usage similar to that used in the healthy subject study...
June 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28363584/upper-gastrointestinal-toxicity-associated-with-long-term-aspirin-therapy-consequences-and-prevention
#19
REVIEW
Carl J Lavie, Colin W Howden, James Scheiman, James Tursi
Antiplatelet therapy represents a fundamental part of preventive management for patients who are at risk of a secondary cardiovascular disease (CVD) event. In most cases, the antiplatelet regimen is based on low-dose aspirin, a drug that is highly effective in reducing the incidence of CVD events, but is associated with a substantial risk of gastrointestinal (GI) toxicity. The dyspeptic symptoms, which can result from aspirin administration, and which may occur with or without associated ulceration and bleeding, may lead patients to discontinue therapy, thus increasing their CVD risk...
May 2017: Current Problems in Cardiology
https://www.readbyqxmd.com/read/28361440/acid-suppressive-therapy-and-risk-of-infections-pros-and-cons
#20
REVIEW
Leon Fisher, Alexander Fisher
This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on the potential of ASDs to contribute to infections-bacterial, parasitic, fungal, protozoan and viral, particularly in the elderly, comprehensively and critically discusses the growing body of observational literature linking ASD use to a variety of enteric, respiratory, skin and systemic infectious diseases and complications (Clostridium difficile diarrhoea, pneumonia, spontaneous bacterial peritonitis, septicaemia and other)...
March 30, 2017: Clinical Drug Investigation
keyword
keyword
90677
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"